Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Asunto principal
Intervalo de año de publicación
1.
Kidney360 ; 2024 Aug 16.
Artículo en Inglés | MEDLINE | ID: mdl-39151046

RESUMEN

BACKGROUND: Despite being the national's largest ethnic minority, Hispanic Americans have inferior kidney transplant opportunities. San Antonio, Texas is the largest US city with a majority Hispanic population. We assessed the impact of this unique ethnic milieu on waitlisting and transplant practices among Hispanic patients. METHODS: We studied patients >18 years old listed at our center for a kidney-only transplant between 2003-2022. Timing of waitlisting, transplant rates and waitlist outcomes were compared between Hispanic and non-Hispanic White patients. RESULTS: We evaluated 11,895 patients, of whom 67% (n = 8,008) were Hispanic, and 20% (n = 2,341) were White. Preemptive listing was less frequent in Hispanic patients (18% vs 37%). One-third of listed Hispanic patients (37%) and half of White patients (50%) were transplanted, with living-donor kidney transplant performed in 59% (n = 1,755) and 77% (n = 898), respectively. Adjusting for age, sex, blood type, preemptive listing, immunologic sensitization, education, employment, and listing era, Hispanic patients remained less likely to receive a deceased-donor transplant (HR 0.82, 95% CI 0.71 - 0.95). On covariate adjustment, White patients were more likely to experience waitlist death or deterioration (HR 1.23, 95% CI 1.12 - 1.36). CONCLUSIONS: Although waitlist attrition was more favorable among Hispanic patients, waitlist registration was delayed and kidney transplants less frequent compared to White patients. These data demonstrate that majority status alone does not mitigate ethnic disparities in kidney transplantation, while underlining the critical need for ongoing efforts to address physician and patient attitudes relating to suitability of Hispanic patients for transplantation.

2.
Science ; 384(6692): eadl4015, 2024 Apr 12.
Artículo en Inglés | MEDLINE | ID: mdl-38603508

RESUMEN

Therapeutic oligonucleotides are a powerful drug modality with the potential to treat many diseases. The rapidly growing number of therapies that have been approved and that are in advanced clinical trials will place unprecedented demands on our capacity to manufacture oligonucleotides at scale. Existing methods based on solid-phase phosphoramidite chemistry are limited by their scalability and sustainability, and new approaches are urgently needed to deliver the multiton quantities of oligonucleotides that are required for therapeutic applications. The chemistry community has risen to the challenge by rethinking strategies for oligonucleotide production. Advances in chemical synthesis, biocatalysis, and process engineering technologies are leading to increasingly efficient and selective routes to oligonucleotide sequences. We review these developments, along with remaining challenges and opportunities for innovations that will allow the sustainable manufacture of diverse oligonucleotide products.


Asunto(s)
Oligonucleótidos , Oligonucleótidos/síntesis química , Oligonucleótidos/uso terapéutico , Técnicas de Química Sintética
3.
Cureus ; 16(1): e51745, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38187028

RESUMEN

Introduction and aim Gout, the most common form of inflammatory arthritis, arises from hyperuricemia, a condition where elevated levels of uric acid lead to the deposition of monosodium urate (MSU) crystals in the joints. Nevertheless, it's important to note that not all cases of hyperuricemia result in gout. Methodology This cross-sectional study was conducted in the Asir region of Saudi Arabia, targeting primary healthcare physicians (PHPs) specializing in family medicine and general practice. The study utilized a modified electronic questionnaire, inspired by similar studies and aligned with recent guidelines, to assess PHPs' knowledge and practices concerning asymptomatic hyperuricemia (AH) and gout. The questionnaire encompassed the PHPs' demographic data and their knowledge and practices for AH and gout management. Results Out of 201 participating PHPs, the majority were male (68.2%), predominantly aged 25-34 years (73.1%), and practicing as general practitioners (61.2%). A significant proportion of PHPs had less than five years of experience (63.7%). In terms of education, 36.8% attended continuing medical education (CME) on AH or gout, and 66.7% were aware of the related management guidelines. The study revealed that the total knowledge score among PHPs averaged 5.18 out of seven, indicating a moderate level of knowledge. However, their practice level was moderate, with a mean practice score of 6.75 out of 12. The study also found no significant differences in knowledge scores based on gender, age, or years of experience, but significant variations were noted based on medical specialty. Conclusion There is a moderate level of knowledge and practice among PHPs in managing AH and gout in the Asir region. Despite adequate knowledge levels, there appears to be a gap in implementing this knowledge into practice, particularly in long-term management strategies. The findings emphasize the need for ongoing medical education and specialized training programs to bridge these gaps. The study provides a valuable framework for identifying and addressing similar challenges in other regions and medical practices.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA